Retatrutide

Record	What it can tell us
Phase 2 obesity	338 adults over 48 weeks. This peer-reviewed trial supplies weight, safety and heart-rate findings.91,92
TRIUMPH-1	Adults without diabetes were studied through week 80. A selected group continued to week 104. Numerical results here come from the sponsor table that was read; the new journal record was metadata-only in this check.93,94,95
Phase 3 diabetes	537 adults with type 2 diabetes were randomized for 40 weeks. The peer-reviewed abstract reports glucose and weight outcomes.107,108

Status and product identity

No approved retail presentation was identified in the checked sources. A Lilly single-patient expanded-access record is listed as available. In one TGA investigation, a vial sold as retatrutide contained no retatrutide and undeclared semaglutide.^97,106,96

Weight and metabolic results

Weight results use population, dose, duration and missing-data choices specific to each trial.

Retatrutide 12 mg		28.3%
Placebo		2.2%

Percent change from baseline, shown as weight loss. Efficacy estimand in adults without diabetes. The treatment-regimen figures were 25.0% and 3.9%. Sponsor table reviewed.⁹⁴

The selected 104-week extension

Among 532 participants who completed week 80 and could tolerate treatment, the original 12 mg group averaged 30.3% weight loss at week 104. The former-placebo group switched to retatrutide. There was no continued-placebo comparison, so this is not the same analysis as the randomized week-80 result.⁹⁴

537 adults / 40 weeks

At 12 mg, mean HbA1c changed by -1.94 percentage points versus -0.81 percentage points with placebo, and weight changed by -15.3% versus -2.6% under the treatment-regimen analysis. These results do not describe the TRIUMPH-1 population without diabetes.^107,108

Other phase 3 populations

Sponsor disclosures separately report TRIUMPH-2 in type 2 diabetes, TRIUMPH-3 in people with cardiovascular disease, and TRIUMPH-4 in people with knee osteoarthritis without diabetes. Their results should not be pooled into one promise. The TRIUMPH-2 journal record was metadata-only in this check, so its numerical results remain tied to the sponsor disclosure.^103,104,109

Safety and open questions

Trial rates give results for groups following a protocol. Predictions for one person or an unverified online product are beyond these results.

Event	12 mg / placebo
Nausea	42.4% / 14.8%94,98
Diarrhea	32.0% / 13.5%94,98
Constipation	26.1% / 10.9%94,98
Vomiting	25.3% / 4.8%94,98

Dysesthesia and stopping because of side effects

At 12 mg, the sponsor table reported dysesthesia in 12.5% versus 0.9% with placebo. Discontinuation because of an adverse event was 11.3% versus 4.9%. The table reports group rates, not the mechanism, duration or prognosis of an individual's symptom.^94,98

Heart rate and cardiovascular outcomes

Heart rate increased dose-dependently in the phase 2 obesity trial, peaked at week 24 and then declined. In sponsor-reported TRIUMPH-3 results, confidence intervals for both prespecified MACE estimates crossed 1. That result established neither cardiovascular event benefit nor increased harm; a larger outcomes trial remains active.^91,103,105

One spontaneous report overlaps another chapter

One report found by the CJC-1295 alias query also listed retatrutide among several co-suspect products. It overlaps the existing retatrutide report set rather than adding an independent case, and it cannot isolate causality.^169,170

Common questions

Questions here cover study doses, outcomes, safety and access.

01 What doses and titration schedules were actually studied?

Trials used different once-weekly injections and different step-up schedules. The phase 2 obesity trial tested target doses of 1, 4, 8 and 12 mg; the 12 mg group started at 2 mg. TRIUMPH-1 tested target doses of 4, 9 and 12 mg. Those doses and schedules are the study exposures. They provide no instructions for a retail product or an online vial.^91,92,93

02 How much weight loss was seen, in whom, and under which analysis?

In TRIUMPH-1, adults without diabetes in the 12 mg arm averaged 28.3% weight loss at week 80 under the efficacy estimand and 25.0% under the treatment-regimen estimand; placebo results were 2.2% and 3.9%. In the selected 532-person extension, the original 12 mg arm averaged 30.3% weight loss at week 104; participants were completers who tolerated treatment, and there was no continued-placebo comparison. Publisher metadata now identifies a New England Journal of Medicine article, but its full text was not readable in this check, so these figures remain tied to the sponsor table that was read.^94,93,95

03 Can I trust an online vial sold as retatrutide?

A label is not proof. In one TGA investigation, a vial sold as retatrutide contained no retatrutide and contained undeclared semaglutide at about eight times the level in approved semaglutide products. The consumer was hospitalized after uncontrollable vomiting and a torn oesophagus. The finding covers one tested product and supplies no whole-market estimate or proof that verified retatrutide caused the injury.⁹⁶

04 What side effects were reported in TRIUMPH-1?

At 12 mg, the sponsor reported nausea in 42.4%, diarrhea in 32.0%, constipation in 26.1%, vomiting in 25.3%, dysesthesia in 12.5% and discontinuation because of an adverse event in 11.3%. Placebo rates were 14.8%, 13.5%, 10.9%, 4.8%, 0.9% and 4.9%. Sponsor releases supplied these trial-group rates; they do not predict one person's result.^94,98

05 Do the reviewed records validate reconstitution, storage, freezing or travel instructions?

No regulator or trial source behind this chapter validates mixing and storage instructions for an unverified market vial. Retatrutide has no approved retail presentation, and FDA says it cannot be used in compounding under federal law. The TGA substitution finding is a concrete reason that vial size and label claims cannot be assumed to describe the study drug.^14,96,97

06 What happened to lean mass?

A DXA substudy enrolled 189 adults with type 2 diabetes; 103 completed treatment with scans at baseline and week 36. Retatrutide reduced fat mass, and the authors reported that the share of weight loss from lean mass was similar to other obesity treatments. DXA lean mass differs from muscle strength or function, and this substudy does not support a claim that retatrutide has the steepest muscle loss in its class.^99,100

07 How does retatrutide compare with tirzepatide or semaglutide?

No completed published randomized head-to-head result was identified. Cross-trial rankings mix different populations, durations, estimands and dose schedules. A retatrutide-versus-tirzepatide obesity trial is registered, but it is active and has no posted result, so it cannot answer the comparison yet.^43,93,91

08 What happens after stopping, and is there a maintenance dose?

The sources contain no completed randomized stopping result or proven maintenance dose. A phase 3b maintenance study is active without results. The TRIUMPH-1 extension studied continued treatment and a former-placebo group that switched to retatrutide; it was not a withdrawal trial.^101,94

09 Is there evidence for stacking retatrutide with another drug or peptide?

The retatrutide trial inventory contains no controlled stacking study. Its trials used retatrutide under defined protocols and did not test gray-market combinations. Community reports cannot show that a combination is safe, effective or chemically matches its label.^92,100,96

10 Does appetite suppression fade, and do trials prove tolerance?

The trials report group outcomes at scheduled timepoints, not whether a change in one person's appetite means pharmacologic tolerance or that the dose should be raised. An active phase 3b trial is comparing dose-escalation schemes, but it has no posted result.^102,91

11 What evidence exists for switching from semaglutide or tirzepatide?

The supplied primary trial inventory does not establish a switch schedule from semaglutide or tirzepatide to retatrutide. Retatrutide remains investigational, and trial dose-escalation schedules are not conversion rules for products bought online.^97,14,93

12 What is known about heart rate and cardiovascular outcomes?

In the phase 2 obesity trial, heart rate rose in a dose-dependent pattern, peaked at week 24 and then declined. In sponsor-reported TRIUMPH-3 results, the confidence intervals for both prespecified MACE estimates crossed 1; neither cardiovascular event benefit nor increased harm was shown. A larger outcomes trial is still active.^91,103,105

13 Is retatrutide approved, available or legally compoundable?

Retatrutide has no approved retail product. FDA says it is not a component of an FDA-approved drug and cannot be used in compounding under federal law. ClinicalTrials.gov lists an authentic Lilly single-patient expanded-access program as available; that narrow pathway is not retail approval, a general access promise or efficacy evidence.^14,97,106

14 When did effects begin in studies?

The trials measured changes over scheduled visits and provide no dependable day when one person should feel an effect. Early studies found glucose and weight changes over weeks, while the main obesity results were reported at 24, 48, 80 or 104 weeks depending on the study. None of those group timepoints supplies an individual onset estimate.^90,91,94

15 What is dysesthesia or skin sensitivity?

Dysesthesia means altered or unpleasant sensation. In the TRIUMPH-1 sponsor table it was reported in 12.5% of the 12 mg group and 0.9% of placebo. That table reports group rates, not the mechanism, duration or prognosis of an individual's symptom.^94,98

16 What has retatrutide shown in type 2 diabetes?

In peer-reviewed TRANSCEND-T2D-1, 537 adults whose type 2 diabetes was inadequately controlled by diet and exercise were randomized for 40 weeks. At 12 mg, mean HbA1c changed by -1.94 percentage points versus -0.81 percentage points with placebo, and body weight changed by -15.3% versus -2.6% under the treatment-regimen analysis. This population and estimand are different from TRIUMPH-1 obesity results.^107,108

17 What do the knee osteoarthritis and sleep-apnea results show?

Sponsor disclosures report phase 3 changes in knee-pain and sleep-apnea endpoints, but each result must stay tied to its own trial, population and estimand. TRIUMPH-4 studied 445 adults with obesity or overweight and knee osteoarthritis without diabetes for 68 weeks; it did not test cartilage regeneration. The nested sleep-apnea result is not proof that every person with sleep apnea can replace established treatment.^{109,98,110,111}

18 What did the liver-fat substudy find?

In the MRI substudy, 98 participants had a baseline liver-fat measurement and 43 had week-48 MRI data. Higher retatrutide doses produced large reductions in measured liver fat over 24 and 48 weeks. The outcome was imaging-based, without a biopsy-proven clinical liver outcome. The study cannot isolate how much came from the glucagon-receptor arm.^112,92